Anti-EGFR therapies have demonstrated improved efficacy and survival benefits when combined with chemotherapy, and these combinations of chemotherapy plus anti-EGFR mAb or anti-vascular endothelial growth factor mAb are widely used in the current clinical settings as first-line treatment options for advanced CRC [51]. This evidence concerns the gene EGFR and colorectal carcinoma.